SPRY2 and cancer: Other factors, such as GLI2, GLI3, CDON, MEF2C, PITX, SFN, SPRY2, WNT3A and WNT5A (Supplementary Table 6), show a consistent metastasis-promoting role across several cancer types in preclinical studies, which provides a foundation for the development of molecular modifiers against them and their introduction to clinical trials.